Posters

New risk factors for the development and progression of age-related macular degeneration after microsurgical interventions

Poster Details

First Author: K.Kovalchuk UKRAINE

Co Author(s):                     

Abstract Details

Purpose:

Investigation of new risk factors for the development and progression of age-related macular degeneration after microsurgical interventions.

Setting:

The study was prospective.

Methods:

Patients with exudative form of age-related macular degeneration (AMD), after microsurgical intervention, were divided into two groups: with the presence of choroidal neovascularization (CNV) and geographic atrophy (GA) of retinal pigment epithelum (RPE), which extends to the fovea (group 1, n = 9), and in which CNV without GA of RPE (group 2, n = 16). Platelets (Pls) were isolated by centrifugation from the peripheral blood of patients. ATP, ADP agonists adenosine, platelet activation factor (FAT), adrenaline and isadrine at effective concentration (EC50) were used to stimulate Pl. The aggregation was evaluated on a ChronoLog analyzer.

Results:

In the investigated subgroups the hyperreactivity of 5 Pl receptors was determined: purine (A2A-, P2Y- and P2X-) receptors, α2-adrenoreceptor and FAT receptor (p <0.001), and β2-adrenoreceptor hyporeactivity. Only purine P2X- and P2Y-receptors were found to exhibit a clear intergroup boundary of induced Pl agregation. The values of Pl aggregation induced by ATP and ADP, respectively at 78% and 76% or more, can be informative indicators of the presence of CNV and GA of RPE, and can be used to develop risk prediction models for their development. For other receptors, there was no clear boundary between the groups.

Conclusions:

The development of CNV after cataract phacoemulsification and its association with GA of RPE occurred under the influence on the eye structures of the pathogenetic factors of the exudative form of AMD, which was manifested by the hyperreactivity of the same receptors: purine (A2A-, P2Y-, and P2X-, and P2X- FAT receptors.

Financial Disclosure:

None